Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, And Intensive Care Unit Admission In The United States

By PR Newswire NEW BRUNSWICK, N.J., Jan. 6, 2022 /PRNewswire/ — Johnson & Johnson (JNJ) – Get Johnson & Johnson Report (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions. The study was sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson and conducted in partnersh…

Read More